<DOC>
	<DOCNO>NCT02173951</DOCNO>
	<brief_summary>A prospective randomized study Safety , Tolerability Efficacy oral Low dose DFP ( 50 mg/kg/day ) minimally transfuse B-TM 5 transfusion SF reach 500 ng/m either appearance LPI &gt; 0.2 TSAT reach 50 % compare non treatment arm . So aim study : 1 . To determine time well amount transfuse iron ( calculated mg iron/kg ) lead Serum ferritin reach 500 ng /ml LPI appearance &gt; 0.2 well TSAT reach 50 % . 2 . Tolerability safety early low dose DFP 50mg/kg effectiveness postpone prevent SF reaching 1000 ng/ml LPI &gt; 0.6 TSAT &gt; 70 % comparison patient start chelation therapy 3 . Determine adverse event whether drug non drug relate</brief_summary>
	<brief_title>An Algorithm Start Iron Chelation Minimally Transfused Young Beta-thalassemia Major Patients</brief_title>
	<detailed_description>This 1 year randomize prospective study include 64 patient β-thalassemia major 6-36 month , already engage transfusion program receive 5-7 transfusion recruit thalassemia clinic child hospital Ain Shams University . Consents take patient legal guardian explain nature study . Inclusion criteria 1 . Young beta thalassemia major patient ( diagnosed HPLC , CBC ) start transfusion therapy receive 5-7transfusions less , age 6 month . 2 . Pre-transfusional Hb &gt; 9 g/dL . 3 . Serum ferritin ≤ 500ng/ml , transferrin saturation ≤ 50 % . Exclusion criterion : 1 . Beta thalassemia intermedia patient , patient transfusion dependent anemia ( myelodysplasia , chronic hemolytic anemia , pure red cell aplasia , aplastic anemia ) 2 . Patients level ALT &gt; 5 upper limit normal ( ULN ) , serum creatinine &gt; ULN 2 measurement . 3 . Patients history agranulocytosis [ absolute neutrophil count ( ANC ) &lt; 0.5×109/L ] . 4 . Non complaint patient acknowledge review patient 's record . Enrollment period : expect 6 month period mean follow period 12 month . Randomization : patient enrol entered study randomise alternatively either arm 1 2 use close envelope system devise statistician Sample size : It calculate 32 patient study group detect significant difference 0.05 study power 95 % Arms , Groups Cohorts : Sixty-four thalassemia major patient naive chelation therapy randomize 2 group : 1st group : DFP 50 mg/kg 12 month 2nd group : treatment arm Active Comparator arm : iron chelation Included 32 thalassemia major patient low serum ferritin ( ≥500 ) . They receive low dose DFP 50 mg/kg/d . Placebo Comparator arm : blood transfusion Included 32 thalassemia patient low serum ferritin ( ≥500 ) . They receive blood transfusion chelation . Primary end point elevation SF around 1000 ng/ml Tsat &gt; 90 % LPI &gt; 0.6 Both group follow interval 3 month clinically laboratory mean time 12 month . Patients reach serum ferritin ≥1000 subject dose escalation DFP 75 mg/kg/d.in Active Comparator arm start DFP 75MG/KG/D Placebo Comparator arm . Study procedure : 1 . Medical record thalassemia patient review &amp; data gather include : - Age onset . - Transfusion history : - Amount transfusion : gram administer RBCs - Frequency . - Calculation transfusion index ml pack red cell per body weight Kg per year . - Transfusional iron load rate : This calculated blood volume transfuse baseline end study . The average iron content per transfusion unit , derive measure hematocrit . The transfusional iron load rate express mg transfuse iron per kg body weight per day . - History viral hepatitis ( hepatitis B C virus ) . 2 . Laboratory investigation : 1 . Pre-transfusion Complete blood picture ( Both manual electronic ANC ) . 2 . Liver kidney function . 3 . LPI , Serum Ferritin , serum iron transfer saturation measurement : Serum ferritin , transfer saturation ( TSAT ) LPI check prior transfusion base line , 3 , 6 , 9 , 12 month interval . Positive predictive value LPI estimate relation TSAT , SF , frequency blood transfusion , transfusion index , transfusional iron load rate patient start oral chelation therapy . Compliance ICT : Compliance chelation therapy assess review patient self-report dose-taking appropriate number dos take day check prescription refill measure amount drug retain bottle ; cutoff point 70 % consider poor compliance regimen .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Young beta thalassemia major patient ( diagnosed HPLC , CBC ) start transfusion therapy receive 57transfusions less , age 6 month . 2 . Pretransfusional Hb &gt; 9 g/dL . 3 . Serum ferritin ≤ 500ng/ml , transferrin saturation ≤ 50 % . 1 . Beta thalassemia intermedia patient , patient transfusion dependent anemia ( myelodysplasia , chronic hemolytic anemia , pure red cell aplasia , aplastic anemia ) 2 . Patients level ALT &gt; 5 upper limit normal ( ULN ) , serum creatinine &gt; ULN 2 measurement . 3 . Patients history agranulocytosis [ absolute neutrophil count ( ANC ) &lt; 0.5×109/L ] . 4 . Non complaint patient acknowledge review patient 's record .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>young minimally transfused beta thalassemia major</keyword>
	<keyword>labile plasma iron ( LPI )</keyword>
	<keyword>Transferrin saturation ( TSAT )</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Transfusional iron load rate</keyword>
	<keyword>Transfusion unit</keyword>
</DOC>